Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment
11:33am, Wednesday, 25'th Feb 2026
But beneath the selloff, something unusual has emerged.
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
09:56am, Wednesday, 25'th Feb 2026
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S
Ozempic Price War - Novo Nordisk Slashes Prices By 50%
09:13am, Wednesday, 25'th Feb 2026
Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday's premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S.
Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion
08:53am, Wednesday, 25'th Feb 2026
The pharma giant will license drug-delivery technologies from Vivtex to develop next-generation oral medicines for obesity, diabetes and associated diseases.
Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
08:03am, Wednesday, 25'th Feb 2026
Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesd
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
08:00am, Wednesday, 25'th Feb 2026
Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities
Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low
07:08am, Wednesday, 25'th Feb 2026
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low.
These 4 charts show the scale of Novo Nordisk's woes
05:32am, Wednesday, 25'th Feb 2026
Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk. The Danish company is less diversified than current and future competitors, and increasingly exposed to th
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027
04:14am, Wednesday, 25'th Feb 2026
Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
12:30am, Wednesday, 25'th Feb 2026
Turning $100,000 into $1 million is a task few stocks can accomplish. Novo Nordisk doesn't seem likely to do so, especially given the challenges it is facing.
Market Today: AMD--Meta AI pact, WBD bid war, Stripe at $159B
05:35pm, Tuesday, 24'th Feb 2026
Guru Stock PicksPaul Singer has made the following transactions:Reduce in LUV by 8.86%Stock News Meta taps AMD for AI buildout: Meta Platforms (META) signed a m
Novo Nordisk: The New PayPal?
04:08pm, Tuesday, 24'th Feb 2026
Novo Nordisk faces renewed pressure after CagriSema failed to match Eli Lilly's tirzepatide in a key Phase 3 trial. Despite margin compression and weak 2026 guidance, NVO remains a cash-generative lea
Novo Announces Proposed Private Placement
03:51pm, Tuesday, 24'th Feb 2026
Not for release to US wire service or distribution in the United States PERTH, Australia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO) (TSX: NVO)
Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss
03:38pm, Tuesday, 24'th Feb 2026
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly's Zepbound.
Ozempic, Wegovy prices to drop up to 50% as Novo Nordisk's rivalry with Eli Lilly heats up: report
03:26pm, Tuesday, 24'th Feb 2026
Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by as much as 50%, according to a report.
